| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
HSD-016 targets 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that catalyzes the conversion of inactive cortisone to active cortisol. By inhibiting 11β-HSD1, HSD-016 reduces local cortisol production in tissues such as adipose tissue and liver, thereby improving insulin sensitivity and glucose metabolism. This mechanism makes it a valuable tool for studying metabolic disorders including type 2 diabetes and metabolic syndrome.
|
|---|---|
| ln Vitro |
In vitro, HSD-016 demonstrates potent inhibition of 11β-HSD1 across multiple species. It exhibits IC50 values of 11 nM for human 11β-HSD1, 1 nM for mouse 11β-HSD1, and 8 nM for rat 11β-HSD1. The compound's strong inhibitory activity across species makes it useful for translational research in metabolic disease models.
|
| ln Vivo |
In vivo, HSD-016 is orally active and has been studied for its effects on glucose metabolism and insulin sensitivity. As an 11β-HSD1 inhibitor, it reduces tissue-specific cortisol production, which may improve glycemic control and metabolic parameters in models of diabetes and metabolic syndrome. However, specific in vivo efficacy data and dosing details have not been extensively detailed in the available literature.
|
| Enzyme Assay |
For in vitro enzyme assays, recombinant human, mouse, or rat 11β-HSD1 proteins are incubated with a substrate (such as cortisone) and the cofactor NADPH in assay buffer. The test compound is added at various concentrations (0.1-1000 nM). Enzyme activity is measured by monitoring the conversion of cortisone to cortisol using HPLC, LC-MS, or radiometric methods. IC50 values are calculated by fitting dose-response curves.
|
| Cell Assay |
For cell-based assays, adipocytes, hepatocytes, or other relevant cell types expressing 11β-HSD1 are treated with HSD-016 at concentrations ranging from 0.1-10 µM. 11β-HSD1 activity is assessed by measuring cortisol production from cortisone in cell lysates or conditioned media using ELISA or LC-MS. Insulin sensitivity can be assessed by measuring glucose uptake or insulin signaling pathway activation.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of diabetes and metabolic syndrome (such as high-fat diet-induced obese mice or db/db mice) would be used. HSD-016 would be administered orally at doses determined from pharmacokinetic studies. Blood glucose, insulin levels, and glucose tolerance would be assessed. Tissue cortisol levels and 11β-HSD1 activity would be measured to confirm target engagement.
|
| ADME/Pharmacokinetics |
HSD-016 is orally active with favorable pharmacokinetic properties. It is soluble in DMSO at 80 mg/mL (155.5 mM). For in vivo administration, it can be formulated in 10% DMSO + 90% corn oil at 3.3 mg/mL. Storage is recommended at -20°C for powder (3 years) and -80°C for solutions (1 year). Further detailed PK parameters would be available from the primary literature.
|
| Toxicity/Toxicokinetics |
HSD-016 is a research compound intended for laboratory use only and is not for human or veterinary use. As an 11β-HSD1 inhibitor, it may affect glucocorticoid metabolism and should be handled with appropriate safety precautions. Comprehensive toxicology studies would be required before any clinical development.
|
| References | |
| Additional Infomation |
HSD 016 is being investigated in the clinical trial NCT00838461 (a study evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HSD-016).
HSD-016 is a potent, selective, orally active 11β-HSD1 inhibitor with IC50 values of 11 nM (human), 1 nM (mouse), and 8 nM (rat). It is used in research to study diabetes and metabolic syndrome. HSD-016 is a research tool and is not approved for clinical use. |
| Molecular Formula |
C21H21F7N2O3S
|
|---|---|
| Molecular Weight |
514.46
|
| Exact Mass |
514.116
|
| Elemental Analysis |
C, 49.03; H, 4.11; F, 25.85; N, 5.45; O, 9.33; S, 6.23
|
| CAS # |
946396-92-5
|
| PubChem CID |
16721125
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.597
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
817
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S(C1C=CC=C([C@](C)(C(F)(F)F)O)C=1)(N1CCN(C2C=CC(=CC=2C(F)(F)F)F)C[C@H]1C)(=O)=O
|
| InChi Key |
ZWASRJHIEFYJGL-BFUOFWGJSA-N
|
| InChi Code |
InChI=1S/C21H21F7N2O3S/c1-13-12-29(18-7-6-15(22)11-17(18)20(23,24)25)8-9-30(13)34(32,33)16-5-3-4-14(10-16)19(2,31)21(26,27)28/h3-7,10-11,13,31H,8-9,12H2,1-2H3/t13-,19-/m1/s1
|
| Chemical Name |
(R)-1,1,1-trifluoro-2-(3-(((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)sulfonyl)phenyl)propan-2-ol
|
| Synonyms |
HSD-016 HSD-16HSD 16HSD 016 HSD016 HSD16
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~194.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.86 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9438 mL | 9.7189 mL | 19.4379 mL | |
| 5 mM | 0.3888 mL | 1.9438 mL | 3.8876 mL | |
| 10 mM | 0.1944 mL | 0.9719 mL | 1.9438 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
